Ultralife Corporation (ULBI) is a publicly traded Industrials sector company. As of May 21, 2026, ULBI trades at $6.12 with a market cap of $101.61M and a P/E ratio of -0.15. ULBI moved +0.17% today. Year to date, ULBI is +0.17%; over the trailing twelve months it is +7.73%. Its 52-week range spans $4.07 to $10.09. Rallies surfaces ULBI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in ULBI news today?
Ultralife Notes Record Backlog Despite Q1 Disruptions and Elevated Costs: Ultralife posted a first-quarter fiscal 2026 loss as lower sales, production disruptions and elevated one-time charges weighed on results. The company secured a record backlog and pointed to new product activity as catalysts for future revenue growth.
WHITMORE BRADFORD T bought 53.13K (~$359.11K) on Mar 16, 2026.
WHITMORE BRADFORD T bought 100.64K (~$636.49K) on Mar 13, 2026.
WHITMORE BRADFORD T bought 33.74K (~$201.31K) on Mar 12, 2026.
ULBI Analyst Consensus
ULBI analyst coverage data. Average price target: $0.00.
Common questions about ULBI
What changed in ULBI news today?
Ultralife Notes Record Backlog Despite Q1 Disruptions and Elevated Costs: Ultralife posted a first-quarter fiscal 2026 loss as lower sales, production disruptions and elevated one-time charges weighed on results. The company secured a record backlog and pointed to new product activity as catalysts for future revenue growth.
Does Rallies summarize ULBI news?
Yes. Rallies summarizes ULBI news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ULBI research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ULBI. It does not provide personalized investment advice.
